Cargando…
Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines
Sorafenib, a protein kinase inhibitor approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma, has been repeatedly reported to induce ferroptosis by possibly involving inhibition of the cystine/glutamate antiporter, known as system x(c)(−). Using a combination of wel...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277867/ https://www.ncbi.nlm.nih.gov/pubmed/34257282 http://dx.doi.org/10.1038/s41419-021-03998-w |